Cadrenal Therapeutics, Inc. CVKD
for life-threatening immune and thrombotic conditions. As a result of our acquisition of a 12-lipoxygenase ("12-LOX") platform
of assets in December 2025 (as described in more detail below), we transitioned our primary strategic focus to the development of CAD-1005
for the treatment of immune-mediated and thrombotic disorders. Our lead product candidate, CAD-1005, is a first-in-class selective 12-LOX
inhibitor being developed to treat heparin-induced thrombocytopenia ("HIT"), a deadly immune-mediated thrombotic disorder.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2007 |
|---|---|---|---|---|---|
| Cost of revenue | — | — | $220.1K | — | $220.1K |
| R&D | $4.1M | $4.2M | $4.1M | $3.0M | — |
| SG&A | $9.4M | $6.8M | $3.5M | $2.3M | — |
| Total operating expenses | $13.5M | $11.0M | $7.6M | $2.7M | — |
| Operating income | -$13.5M | -$11.0M | -$7.6M | -$2.7M | — |
| Interest expense | — | — | $3.5K | $40.2K | — |
| Net income | -$13.2M | -$10.7M | -$8.4M | -$6.7M | — |
| EPS, basic | -6.64 | -8.73 | -9.29 | -0.85 | — |
| EPS, diluted | -6.64 | -8.73 | -9.29 | -0.85 | — |
| Shares, diluted (wtd. avg.) | $2.0M | $1.2M | $899.5K | $7.9M | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2007 |
|---|---|---|---|---|---|
| Cash and equivalents | $4.0M | $10.0M | $8.4M | $32.6K | — |
| Total current assets | $4.3M | $10.1M | $8.5M | $727.6K | — |
| Property, plant and equipment | $5.2K | $6.9K | $2.3K | $1.0K | — |
| Total assets | $4.3M | $10.1M | $8.5M | $778.2K | — |
| Accounts payable | $650.7K | $1.5M | $167.3K | $404.9K | — |
| Short-term debt | — | — | — | $597.1K | — |
| Total current liabilities | $1.6M | $2.7M | $826.9K | $1.3M | — |
| Total liabilities | $1.6M | $2.7M | $826.9K | $6.3M | — |
| Retained earnings | -$39.0M | -$25.7M | -$15.1M | -$6.7M | — |
| Total equity | $2.7M | $7.4M | $7.7M | -$5.6M | — |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2007 |
|---|---|---|---|---|---|
| Operating cash flow | -$12.6M | -$7.4M | -$3.5M | -$1.2M | — |
| Depreciation and amortisation | $6.9K | $1.9K | $2.0K | $1.3K | — |
| Stock-based compensation | $1.9M | $1.4M | $710.4K | $928.0K | — |
| Capital expenditure | $5.1K | $6.5K | $3.3K | $2.3K | — |
| Investing cash flow | -$5.1K | -$6.5K | -$3.3K | -$2.3K | — |
| Financing cash flow | $6.6M | $9.0M | $11.9M | $1.2M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001213900-26-036946.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AKTX | Akari Therapeutics Plc | $1.79T | — | — |
| LLY | ELI LILLY & Co | $1.08T | 50.1x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $663.28B | 25.0x | 6.0% |
| ONC | BeOne Medicines Ltd. | $529.55B | 1,885.6x | 40.2% |
| ABBV | AbbVie Inc. | $453.19B | 108.7x | 8.6% |
| MRK | Merck & Co., Inc. | $370.89B | 20.6x | 1.3% |
| ABT | ABBOTT LABORATORIES | $188.69B | 29.1x | 5.7% |
| PFE | PFIZER INC | $162.16B | 20.9x | -1.6% |